| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443266 | European Journal of Cancer | 2014 | 10 Pages |
Abstract
Taken together, our results show that PARP inhibition has antitumour effects and increases trastuzumab activity in HER2 overexpressing breast cancer. These findings make this novel combination a promising strategy for clinical development.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jetzabel GarcÃa-Parra, Alba Dalmases, Beatriz Morancho, Oriol ArpÃ, Silvia Menendez, MohammadA Sabbaghi, Sandra Zazo, Cristina Chamizo, Juan Madoz, Pilar Eroles, Sonia Servitja, Ignasi Tusquets, Jose Yelamos, Ana Lluch, Joaquin Arribas, Federico Rojo,